Menu
Not yet recruiting NCT06897969

Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

Phase IV Interventional Keloid Scars

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Triamcinolone Acetonide 1 ml of 40 mg/mL suspension, Verapamil Injection.
Who it may be relevant to
Registry conditions: Keloid Scars. Basic parameters: 10 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Pakistan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparison of Intralesional Triamcinolone and Intralesional Verapamil in the Treatment of Keloids

Overview

This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.

Interventions

  • Drug Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
    Monthly intralesional injection
  • Drug Verapamil Injection
    2.5 mg of intralesional Verapamil injection monthly

Primary outcome measures

  • Change in Vancouver Scar Score [Time frame: Vancouver Scar score will be measured at baseline (before treatment assignment) and then 4-weeks after completion of treatment - 16-weeks after randomization.]

Eligibility criteria

Inclusion criteria

  • size of keloid1-5 cm,
  • on any site of the body,
  • duration less then five years and
  • baseline Vancouver scar score of more the or equal to 5

Exclusion criteria

  • Pregnant or lactating women,
  • family history of keloids,
  • acromegaly, and
  • congestive cardiac diseases

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Pakistan · 1 center
  • Nishtar Medical University & Hospital — Multan

Publications

  • Kuang J, An P, Li W. Comparative efficacy and safety of verapamil and triamcinolone in keloid and hypertrophic scar treatment: a meta-analysis. J Cosmet Laser Ther. 2021 Feb 17;23(1-2):26-34. doi: 10.1080/14764172.2021.1950765. Epub 2021 Jul 18. PMID 34278918
  • Uzair M, Butt G, Khurshid K, Pal SS. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Our Dermatol Online. 2015;6(3):280-4.
  • Saki N, Mokhtari R, Nozari F. Comparing the Efficacy of Intralesional Triamcinolone Acetonide With Verapamil in Treatment of Keloids: A Randomized Controlled Trial. Dermatol Pract Concept. 2019 Jan 31;9(1):4-9. doi: 10.5826/dpc.0901a02. eCollection 2019 Jan. PMID 30775139

Identifiers

NCT: NCT06897969 · 21467/NMU

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗